Tzingounis V A, Aksu M F, Greenblatt R B
JAMA. 1978 Apr 21;239(16):1638-41.
Estriol was administered for a six-month period as estrogen replacement therapy to 52 symptomatic postmenopausal women. Assays of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrone, and estradiol were performed before and during therapy. During this period of administration, vaginal cytology, cervical mucus, and endometrial studies were performed. Clinical effectiveness was directly related to dosage (2 to 8 mg/day). Estriol (8 mg/day) failed to induce endometrial proliferation and proved a poor suppressor of FSH and LH. This agent's capacity to relieve vasomotor instability and improve vaginal maturation without notable side effects is sufficient reason to include this drug in the management of the postmenopausal syndrome.
对52名有症状的绝经后妇女给予雌三醇进行为期6个月的雌激素替代疗法。在治疗前和治疗期间进行血清促卵泡激素（FSH）、促黄体生成素（LH）、雌酮和雌二醇的测定。在给药期间，进行了阴道细胞学、宫颈黏液和子宫内膜研究。临床疗效与剂量（2至8毫克/天）直接相关。雌三醇（8毫克/天）未能诱导子宫内膜增生，且对FSH和LH的抑制作用较差。该药物缓解血管舒缩不稳定和改善阴道成熟度且无明显副作用的能力，足以使其被纳入绝经后综合征的治疗方案。
